Quorum Innovations Announces Consumer Rebrand: Introducing MyGutGuardian™ Powered by QI-601®

The same patented, research-backed technology receives a new consumer-friendly identity - My Gut Guardian

SARASOTA, FL, UNITED STATES, August 13, 2026 /EINPresswire.com/ -- Quorum Innovations today announced that its flagship consumer product, QI-601^®, will now be marketed under the new consumer brand MyGutGuardian™ Powered by QI-601^®.

The name change reflects the company’s commitment to making its breakthrough science more understandable and approachable for consumers while maintaining the same patented technology that has earned international attention from researchers, healthcare professionals, and the media.

“MyGutGuardian tells people exactly what this product is designed to do,” said Nicholas T. Monsul, M.D., co-founder of Quorum Innovations. “The science has not changed—only the name. Consumers will continue to receive the same innovative technology powered by QI-601.”

Developed by physician-scientists Nicholas T. Monsul, M.D., and Eva Ann Berkes, M.D., QI-601 is a patented, non-drug, non-systemic biofilm postbiotic technology designed to bind and retain micro- and nanoplastics within the digestive tract so they can be eliminated through the body’s normal digestive process.

As concern continues to grow over the presence of micro- and nanoplastics in food, water, beverages, and everyday consumer products, MyGutGuardian offers consumers a simple, once-daily supplement developed specifically to address this emerging environmental health challenge.

The technology behind MyGutGuardian has received significant scientific recognition, including:

More than 50 issued patents, with additional patents pending.
Research accepted for presentation at leading scientific conferences.
Technology developed through groundbreaking research supported by two Direct-to-Phase II programs from the U.S. Defense Advanced Research Projects Agency (DARPA).

Participation in the U.S. Department of Health and Human Services’ Strategic Testing to Reduce the Impact of Microplastics (STOMP) initiative, where Quorum Innovations was invited to help advance national discussions surrounding microplastic solutions.

International media coverage highlighting the company’s innovative approach to addressing microplastic exposure.
“MyGutGuardian is a name people immediately understand,” said Eva Ann Berkes, M.D., co-founder of Quorum Innovations. “Our goal has always been to translate groundbreaking science into practical solutions that consumers can incorporate into their daily wellness routines. This new brand better reflects that mission.”

Consumers can be confident that although the packaging and branding are changing, the product inside remains the same trusted formulation powered by the company’s proprietary QI-601 technology.

The company believes the MyGutGuardian brand will better communicate the product’s purpose to consumers while strengthening its position across retail, e-commerce, healthcare, and international markets.

Availability

MyGutGuardian™ Powered by QI-601^® will begin appearing on product packaging, marketing materials, and consumer communications immediately. During the transition, consumers may see either the QI-601 or MyGutGuardian branding while inventories are updated. Both names represent the same patented formulation and technology developed by Quorum Innovations.

About Quorum Innovations

Quorum Innovations is a U.S.-based biotechnology company focused on developing patented, science-driven technologies that address emerging environmental health challenges. Founded by physician-scientists Nicholas T. Monsul, M.D., and Eva Ann Berkes, M.D., the company has pioneered innovative biofilm-based technologies designed to provide practical consumer solutions backed by rigorous scientific research.

Pamela McCoy
Media Relations
Quorum Innovations

Pam.media@quoruminnovations.com
(727)314-2071

Pamela McCoy
Quorum Innovations
+1 (727) 314-2071
email us here